CD38 and plasma cell myeloma: They demonstrated in vitro that VD is a key molecule for restoring and maintaining the effector functions of myeloma-associated macrophages and that VD supplementation in combination with IMiDs can enhance the therapeutic efficacy of anti-CD38 antibodies.